WEBVTT 00:00:00.000 --> 00:00:02.200 Welcome back to the Deep Dive. You sent us a 00:00:02.200 --> 00:00:05.040 truly fascinating stack of sources this time. 00:00:05.160 --> 00:00:07.559 It's an incredible story. It really is. It details 00:00:07.559 --> 00:00:11.199 the operations of a company that is somehow both 00:00:11.199 --> 00:00:14.820 a pretty recent market entrant and at the same 00:00:14.820 --> 00:00:17.120 time one of the most powerful names in global 00:00:17.120 --> 00:00:19.500 medicine. We're talking about a powerhouse that 00:00:19.500 --> 00:00:23.320 has completely redefined what aggressive growth 00:00:23.320 --> 00:00:25.449 looks like in the pharmaceutical world. It's 00:00:25.449 --> 00:00:28.370 an incredible case study, really, in scale, speed 00:00:28.370 --> 00:00:32.229 and strategic financial maneuvering. When you 00:00:32.229 --> 00:00:34.490 look at the sheer market footprint of AbbVie 00:00:34.490 --> 00:00:37.000 Inc. It's hard to believe it only became a public 00:00:37.000 --> 00:00:39.640 entity just over a decade ago. It feels like 00:00:39.640 --> 00:00:41.579 this established giant, but it's still relatively 00:00:41.579 --> 00:00:44.659 new. And that newness is, I think, key to understanding 00:00:44.659 --> 00:00:47.200 its strategy. Our mission today is to really 00:00:47.200 --> 00:00:49.340 pull apart this corporate entity. Go beyond the 00:00:49.340 --> 00:00:51.859 press releases. Exactly. Move past the glossy 00:00:51.859 --> 00:00:54.219 press releases and understand the three core 00:00:54.219 --> 00:00:56.579 dynamics that define it. How they built their 00:00:56.579 --> 00:00:59.359 initial multi -billion dollar empire on blockbuster 00:00:59.359 --> 00:01:02.119 drugs and are now managing a massive, massive 00:01:02.119 --> 00:01:05.000 transition. Then there's their... aggressive, 00:01:05.180 --> 00:01:07.799 almost industrial scale mergers and acquisitions 00:01:07.799 --> 00:01:11.280 model, their M &A model. And finally, the significant 00:01:11.280 --> 00:01:15.099 legal pricing and governmental scrutiny that 00:01:15.099 --> 00:01:17.540 really shadows every single billion dollar deal 00:01:17.540 --> 00:01:19.560 they make. Exactly. We're talking about an American 00:01:19.560 --> 00:01:21.760 pharmaceutical company headquartered in North 00:01:21.760 --> 00:01:24.420 Chicago, Illinois. And when we call them a giant, 00:01:24.599 --> 00:01:26.760 we are not exaggerating. I mean, the sources 00:01:26.760 --> 00:01:29.260 confirm they are ranked the sixth largest biomedical 00:01:29.260 --> 00:01:32.359 company globally by revenue. Sixth largest. This 00:01:32.359 --> 00:01:34.560 isn't some small time player. They're sitting 00:01:34.560 --> 00:01:38.280 comfortably at 77th on the Fortune 500 and 108th 00:01:38.280 --> 00:01:41.340 on the Forbes Global 2000. I mean, that's staggering 00:01:41.340 --> 00:01:43.260 influence across the entire corporate landscape, 00:01:43.400 --> 00:01:45.239 not just pharma. And we really have to start 00:01:45.239 --> 00:01:47.680 with the origin story because it explains the. 00:01:48.730 --> 00:01:51.510 The unique DNA they have. AbbVie was officially 00:01:51.510 --> 00:01:54.370 formed in 2012 as a corporate spinoff from Abbott 00:01:54.370 --> 00:01:57.670 Laboratories. It became a fully public standalone 00:01:57.670 --> 00:02:02.170 entity in January 2013. Now, corporate spinoffs 00:02:02.170 --> 00:02:04.189 are common, but this one was just monumental. 00:02:04.829 --> 00:02:08.169 Abbott basically separated its research based 00:02:08.169 --> 00:02:10.389 pharmaceutical division, the high risk, high 00:02:10.389 --> 00:02:13.430 reward drug discovery unit, from its more stable, 00:02:13.530 --> 00:02:15.990 broader medical device and diagnostics business. 00:02:16.310 --> 00:02:18.319 So they were born, you know, fully. Formed as 00:02:18.319 --> 00:02:20.819 a pure play pharmaceutical powerhouse, instantly 00:02:20.819 --> 00:02:23.800 focused on life sciences and therapeutics. I 00:02:23.800 --> 00:02:25.360 always find the naming conventions in pharma 00:02:25.360 --> 00:02:27.680 so fascinating. They're very deliberate. They 00:02:27.680 --> 00:02:29.860 are. They try to capture both science and aspiration. 00:02:30.219 --> 00:02:32.139 And here's a great little nugget for you, the 00:02:32.139 --> 00:02:35.159 listener. The name Abbey is a neat blend. They 00:02:35.159 --> 00:02:37.780 took Ab from the former parent, Abbott, and then 00:02:37.780 --> 00:02:40.419 added V, which is a reference to the Latin root 00:02:40.419 --> 00:02:42.599 for life. It's clever. It's a very clean way 00:02:42.599 --> 00:02:44.460 to signal their purpose. But as we're about to 00:02:44.460 --> 00:02:47.740 see, that... That high -minded purpose sometimes 00:02:47.740 --> 00:02:50.280 conflicts with the aggressive business reality 00:02:50.280 --> 00:02:52.360 we're about to unpack. And that aggressive reality, 00:02:52.500 --> 00:02:55.080 it requires management on a truly global scale. 00:02:55.280 --> 00:02:56.919 I mean, this is a company that has to manage 00:02:56.919 --> 00:02:59.840 operations across over 170 countries worldwide 00:02:59.840 --> 00:03:03.560 and employs 55 ,000 people. Wow. We should also 00:03:03.560 --> 00:03:05.740 note the leadership structure, which has defined 00:03:05.740 --> 00:03:07.860 the company's trajectory since it was founded. 00:03:08.060 --> 00:03:10.520 Richard A. Gonzalez has been a defining figure. 00:03:10.740 --> 00:03:13.949 He's currently the chairman. However... There 00:03:13.949 --> 00:03:16.069 was a pretty recent transition in the top seat. 00:03:16.270 --> 00:03:19.729 Robert Michael took over as CEO in June 2024. 00:03:20.169 --> 00:03:22.729 So a new chapter. A new chapter, yeah. But the 00:03:22.729 --> 00:03:24.530 established growth framework, the one Gonzalez 00:03:24.530 --> 00:03:27.030 was so instrumental in building, that remains 00:03:27.030 --> 00:03:29.250 the central operating principle. And that growth 00:03:29.250 --> 00:03:31.650 framework is what we need to jump into now because 00:03:31.650 --> 00:03:34.189 it all starts with the financials and, you know, 00:03:34.189 --> 00:03:36.969 specifically the blockbusters. This deep dive 00:03:36.969 --> 00:03:39.729 is going to focus heavily on what is probably 00:03:39.729 --> 00:03:41.669 the highest stakes transition a pharmaceutical 00:03:41.669 --> 00:03:44.169 company can face. Oh, absolutely. That shift 00:03:44.169 --> 00:03:46.689 from depending on one massive revenue pillar 00:03:46.689 --> 00:03:51.150 to a diversified portfolio, it's like a near 00:03:51.150 --> 00:03:53.069 -death experience, financially speaking, for 00:03:53.069 --> 00:03:55.169 any company that fails it. The financials are 00:03:55.169 --> 00:03:57.889 the essential foundation here. They explain AbbVie's 00:03:57.889 --> 00:04:01.430 aggressive strategy in both R &D and M &A. When 00:04:01.430 --> 00:04:04.189 you looked at the 2024 data, we see total revenue 00:04:04.189 --> 00:04:09.099 hitting... 56 .33 billion U .S. dollars. 56 billion. 00:04:09.280 --> 00:04:11.979 Just think about that number. That's a revenue 00:04:11.979 --> 00:04:15.199 stream so colossal that it allows them to immediately 00:04:15.199 --> 00:04:18.240 absorb a multibillion dollar acquisition or a 00:04:18.240 --> 00:04:20.759 major legal settlement without even flinching, 00:04:20.759 --> 00:04:23.180 which is exactly what we'll get into later. Their 00:04:23.180 --> 00:04:27.759 operating income for 2024 was also huge. 9 .137 00:04:27.759 --> 00:04:30.930 billion. That's incredible. This financial gravity, 00:04:31.009 --> 00:04:33.389 it dictates their place in the industry, and 00:04:33.389 --> 00:04:35.810 it enables the kind of risk -taking you need 00:04:35.810 --> 00:04:38.310 for pharma growth. And when you trace how they 00:04:38.310 --> 00:04:41.129 built that foundation, one name just absolutely 00:04:41.129 --> 00:04:45.050 dominates the conversation. Humira. Humira. Adalimumab. 00:04:45.089 --> 00:04:48.610 For years, Humira was the quintessential pharmaceutical 00:04:48.610 --> 00:04:51.790 blockbuster. It was an antibody injection approved 00:04:51.790 --> 00:04:54.310 for a massive range of autoimmune diseases, rheumatoid 00:04:54.310 --> 00:04:56.449 arthritis, Crohn's, plaque psoriasis, you name 00:04:56.449 --> 00:04:58.910 it. It was basically a Swiss army knife for inflammation. 00:04:59.319 --> 00:05:01.660 It was more than a blockbuster. For a long time, 00:05:01.699 --> 00:05:03.600 it was the biggest selling drug in the world, 00:05:03.720 --> 00:05:06.480 routinely pulling in over $20 billion a year 00:05:06.480 --> 00:05:09.639 at its peak. This one drug, this single drug, 00:05:09.779 --> 00:05:12.019 was the financial engine of the newly formed 00:05:12.019 --> 00:05:14.540 AbbVie. What's incredible is its staying power. 00:05:14.980 --> 00:05:18.339 Even in 2024, after it had already begun facing 00:05:18.339 --> 00:05:20.860 biosimilar competition in the U .S. market, which 00:05:20.860 --> 00:05:25.480 started in January 2023, even after that, Humira 00:05:25.480 --> 00:05:28.920 still generated a massive $9 billion in revenue. 00:05:29.160 --> 00:05:31.839 $9 billion, still. That's 16 % of their total 00:05:31.839 --> 00:05:34.120 revenue. I need to pause on that $9 billion figure. 00:05:34.199 --> 00:05:36.839 That is a gigantic revenue stream. But the key 00:05:36.839 --> 00:05:39.300 phrase you just mentioned is biosimilar competition. 00:05:39.819 --> 00:05:42.120 For the listener who might not track pharma that 00:05:42.120 --> 00:05:43.860 closely, can you quickly explain the difference? 00:05:43.939 --> 00:05:46.860 What's a biosimilar versus a generic? And why 00:05:46.860 --> 00:05:50.000 was Humira's patent cliff in 2023 such a massive 00:05:50.000 --> 00:05:52.680 corporate event? That's a crucial distinction, 00:05:52.920 --> 00:05:55.769 yeah. Generics are chemically identical to small 00:05:55.769 --> 00:05:58.589 molecule drugs. Think aspirin or Tylenol. Simple 00:05:58.589 --> 00:06:01.589 stuff. Biosimilars, however, are for large biologic 00:06:01.589 --> 00:06:03.589 drugs like Humira, which are made in living systems, 00:06:03.649 --> 00:06:06.329 usually cell cultures. So they're more complex. 00:06:06.550 --> 00:06:08.709 Much more complex. Because they're complex proteins, 00:06:08.949 --> 00:06:11.329 they can't be perfectly replicated. So a biosimilar 00:06:11.329 --> 00:06:14.930 is a highly similar version with no clinically 00:06:14.930 --> 00:06:17.329 meaningful difference from the original. The 00:06:17.329 --> 00:06:20.250 term patent cliff is the pharma industry's, let's 00:06:20.250 --> 00:06:23.970 say, euphemism for when the primary patents protecting 00:06:23.970 --> 00:06:27.470 a major drug expire. Very gentle word for a disaster. 00:06:27.689 --> 00:06:31.509 Right. It allows these cheaper competitors, biosimilars 00:06:31.509 --> 00:06:34.129 in this case, to flood the market. And when you 00:06:34.129 --> 00:06:37.589 lose $10 or $15 billion in revenue almost overnight, 00:06:37.769 --> 00:06:41.110 it's a terrifying financial drop. So the clock 00:06:41.110 --> 00:06:43.509 has been ticking loudly on that $9 billion revenue 00:06:43.509 --> 00:06:46.519 stream. Which is exactly why the focus has shifted 00:06:46.519 --> 00:06:49.240 entirely to its successors. They had to transition 00:06:49.240 --> 00:06:51.279 smoothly to maintain that multibillion -dollar 00:06:51.279 --> 00:06:53.800 cash flow, and the sources show they have executed 00:06:53.800 --> 00:06:56.079 a, well, a brilliant dual -track replacement 00:06:56.079 --> 00:06:59.360 strategy. Absolutely. The main successor is Skyrizi, 00:06:59.399 --> 00:07:02.459 or Razankizumab. Skyrese is also an autoimmune 00:07:02.459 --> 00:07:05.000 treatment, but it uses a more targeted mechanism. 00:07:05.259 --> 00:07:08.439 It's an interleukin -23 or IL -23 inhibitor. 00:07:08.480 --> 00:07:10.860 So it's more precise. Exactly. It specifically 00:07:10.860 --> 00:07:13.959 blocks the signaling pathway of IL -23, which 00:07:13.959 --> 00:07:16.660 is a key driver of inflammation in diseases like 00:07:16.660 --> 00:07:19.519 psoriasis and Crohn's. The whole strategy here 00:07:19.519 --> 00:07:22.680 is better efficacy and a potentially cleaner 00:07:22.680 --> 00:07:24.860 side effect profile than the last generation. 00:07:25.139 --> 00:07:27.480 And that better efficacy is translating directly 00:07:27.480 --> 00:07:30.610 into revenue. Scarisi is now the company's clear 00:07:30.610 --> 00:07:34.230 powerhouse. In 2024, it brought in a staggering 00:07:34.230 --> 00:07:39.350 $11 .7 billion in revenue. $11 .7 billion. That's 00:07:39.350 --> 00:07:41.529 21 % of their total revenue. It has effectively 00:07:41.529 --> 00:07:44.790 taken Humira's crown as the primary revenue generator 00:07:44.790 --> 00:07:47.670 in just a few short years, which is just an incredible 00:07:47.670 --> 00:07:50.970 feat of both R &D and marketing. And following 00:07:50.970 --> 00:07:53.329 close behind is the second track of that replacement 00:07:53.329 --> 00:07:57.240 strategy, Rinvok or Upadasatinib. Primarily treats 00:07:57.240 --> 00:07:59.240 arthritis, and it's a different class of drug, 00:07:59.360 --> 00:08:02.459 a JAK inhibitor. RENVOC generated a solid $6 00:08:02.459 --> 00:08:05.949 billion in 2023 revenue. Another 11%. Right. 00:08:06.029 --> 00:08:08.769 11 % of the total. And this dual -pronged strategy 00:08:08.769 --> 00:08:11.509 is critical for risk mitigation. They didn't 00:08:11.509 --> 00:08:13.449 just develop one successor. They developed a 00:08:13.449 --> 00:08:16.389 strong duo. It ensures that if Skyrizi faced 00:08:16.389 --> 00:08:18.990 unexpected regulatory hurdles or market issues, 00:08:19.509 --> 00:08:22.550 RINVOC could step up and provide revenue insurance 00:08:22.550 --> 00:08:25.269 built right into their R &D strategy. So that 00:08:25.269 --> 00:08:27.930 covers the critical autoimmune pillar. But what's 00:08:27.930 --> 00:08:30.790 equally interesting is the deliberate diversification 00:08:30.790 --> 00:08:34.029 beyond that core. And a lot of it was achieved. 00:08:34.700 --> 00:08:36.580 through those massive M &A deals we're going 00:08:36.580 --> 00:08:38.559 to cover in the next section. The acquisition 00:08:38.559 --> 00:08:40.960 of Allergan in particular brought a critical, 00:08:41.039 --> 00:08:43.299 reliable aesthetic and neuroscience component 00:08:43.299 --> 00:08:46.000 that is wildly different from their core focus. 00:08:46.220 --> 00:08:49.200 And that means Botox, which is a massive, reliable 00:08:49.200 --> 00:08:52.639 cash cow. It generated $6 billion in 2024 revenue, 00:08:52.919 --> 00:08:56.220 matching RENVOC at 11 % of total revenue. It's 00:08:56.220 --> 00:08:57.480 almost funny. When you think about a pharmaceutical 00:08:57.480 --> 00:08:59.320 company, you might not immediately think of the 00:08:59.320 --> 00:09:02.340 cosmetic giant that defined a generation of anti 00:09:02.340 --> 00:09:04.960 -aging treatments. But that cash flow is crucial. 00:09:05.240 --> 00:09:08.299 And Botox also has significant therapeutic applications 00:09:08.299 --> 00:09:11.519 in neurology treating migraines, spasms, other 00:09:11.519 --> 00:09:14.700 conditions. It's a hugely flexible asset. Beyond 00:09:14.700 --> 00:09:18.120 the cosmetic side, we also see a very heavy sustained 00:09:18.120 --> 00:09:21.220 investment in these high value specialty fields 00:09:21.220 --> 00:09:24.120 like hematology and oncology. This is a deliberate 00:09:24.120 --> 00:09:26.840 expansion designed to capture premium pricing 00:09:26.840 --> 00:09:30.299 and treat complex diseases. For instance, Imbruvica, 00:09:30.500 --> 00:09:32.960 or Abrutinib, a blockbuster cancer treatment, 00:09:33.179 --> 00:09:37.379 brought in $3 .3 billion in 2024. Then you have 00:09:37.379 --> 00:09:41.039 Venclexta. For venetoclax, for leukemia and lymphoma, 00:09:41.139 --> 00:09:43.480 that generated $2 .6 billion. And what's fascinating 00:09:43.480 --> 00:09:45.519 here is the evolution of their oncology approach. 00:09:45.720 --> 00:09:47.379 They're not just relying on the older guard. 00:09:47.519 --> 00:09:49.440 Not at all. They also have newer entries like 00:09:49.440 --> 00:09:51.840 Epkinley, a blood cancer therapy co -developed 00:09:51.840 --> 00:09:53.480 with GenMab, which is starting to contribute. 00:09:53.519 --> 00:09:57.460 It reported $0 .1 billion in 2024. This slow 00:09:57.460 --> 00:09:59.879 but steady growth in new oncology assets, it 00:09:59.879 --> 00:10:02.399 really indicates the success of their R &D collaborations 00:10:02.399 --> 00:10:04.899 and targeted acquisitions in this space. And 00:10:04.899 --> 00:10:06.659 then there's the neuroscience portfolio, which 00:10:06.659 --> 00:10:08.669 is expanding beyond just the... Botox applications. 00:10:08.850 --> 00:10:12.600 A Raylar. or caraprazine for schizophrenia and 00:10:12.600 --> 00:10:15.179 bipolar disorder is another significant earner, 00:10:15.179 --> 00:10:19.179 hitting $3 .3 billion in 2024 revenue. Yeah, 00:10:19.320 --> 00:10:22.299 this demonstrates their rapidly solidifying position 00:10:22.299 --> 00:10:24.659 in central nervous system disorders, an area 00:10:24.659 --> 00:10:28.519 notorious for high unmet patient need and very 00:10:28.519 --> 00:10:30.519 complex drug development. And we can't forget 00:10:30.519 --> 00:10:33.039 the important, though smaller, revenue streams 00:10:33.039 --> 00:10:35.980 in infectious diseases. Maveret for hepatitis 00:10:35.980 --> 00:10:39.419 C generated $1 .3 billion, and they still maintain 00:10:39.419 --> 00:10:41.679 older. drugs like Coletra and Norvir in their 00:10:41.679 --> 00:10:44.039 portfolio, which are crucial for global health 00:10:44.039 --> 00:10:46.200 applications. And looking ahead, I mean, the 00:10:46.200 --> 00:10:48.360 company is not resting on its current blockbusters. 00:10:48.500 --> 00:10:50.980 The commitment to pipeline development is crucial. 00:10:51.120 --> 00:10:53.360 They are heavily focusing on advanced treatments 00:10:53.360 --> 00:10:56.059 for neurologic diseases. This includes drug candidates 00:10:56.059 --> 00:10:59.179 for Parkinson's disease like VLF and Tabapodon. 00:10:59.299 --> 00:11:01.679 Right. We also see continued research commitment 00:11:01.679 --> 00:11:05.139 to eye care and cystic fibrosis. This expansion 00:11:05.139 --> 00:11:07.919 is designed to ensure that if Skyrizi or Rynvak 00:11:07.919 --> 00:11:10.320 face their own patent challenges a decade from 00:11:10.320 --> 00:11:12.639 now, the next round of successors is already 00:11:12.639 --> 00:11:15.320 waiting in the wings. So the snapshot is absolutely 00:11:15.320 --> 00:11:18.659 clear. They are a financial machine generating 00:11:18.659 --> 00:11:23.570 over $56 billion a year. They successfully navigated 00:11:23.570 --> 00:11:26.330 the patent cliff of their former top drug by 00:11:26.330 --> 00:11:29.330 strategically substituting it with two new autoimmune 00:11:29.330 --> 00:11:33.230 blockbusters, Skyrizi and Renvac. And they leveraged 00:11:33.230 --> 00:11:36.350 M &A to diversify rapidly and deeply into aesthetics, 00:11:36.590 --> 00:11:39.309 specialty oncology, and neuroscience. But surviving 00:11:39.309 --> 00:11:41.870 is expensive. It is. And that colossal revenue 00:11:41.870 --> 00:11:44.549 base only exists because of their M &A playbook. 00:11:44.710 --> 00:11:47.409 So how exactly did they execute that diversification 00:11:47.409 --> 00:11:49.700 so quickly? That brings us to the industrial 00:11:49.700 --> 00:11:52.039 scale of their acquisition strategy. AbbVie's 00:11:52.039 --> 00:11:53.759 history isn't just defined by internal research. 00:11:53.940 --> 00:11:56.100 It's defined by an aggressive, almost constant 00:11:56.100 --> 00:11:58.860 cycle of mergers and acquisitions. This strategy 00:11:58.860 --> 00:12:01.059 is fundamental. It has to be. If you need to 00:12:01.059 --> 00:12:03.940 replace a massive multi -billion dollar revenue 00:12:03.940 --> 00:12:07.340 stream quickly, you don't wait a decade for internal 00:12:07.340 --> 00:12:10.580 R &D to deliver. You buy a successful phase three 00:12:10.580 --> 00:12:13.399 drug or a proven company and you integrate it 00:12:13.399 --> 00:12:15.970 immediately. Let's trace a timeline because it 00:12:15.970 --> 00:12:18.210 really highlights how systematically they built 00:12:18.210 --> 00:12:21.090 their therapeutic areas beyond that autoimmune 00:12:21.090 --> 00:12:23.889 core they inherited from Abbott. Right after 00:12:23.889 --> 00:12:25.629 the spinoff, they started looking for strategic 00:12:25.629 --> 00:12:29.909 buys. In 2014, they acquired Imovent. A startup, 00:12:30.070 --> 00:12:31.970 right? A startup out of the University of Illinois 00:12:31.970 --> 00:12:34.710 Urbana -Champaign focused on biotherapeutics 00:12:34.710 --> 00:12:37.309 for cancer, infectious disease, and autoimmune 00:12:37.309 --> 00:12:40.090 disorders. It was a relatively small acquisition, 00:12:40.210 --> 00:12:42.649 but it was an early signal that their focus was 00:12:42.649 --> 00:12:45.370 shifting outward for growth. The real game changer 00:12:45.370 --> 00:12:48.049 came in 2015 with the acquisition of the oncology 00:12:48.049 --> 00:12:51.409 firm Pharmacyclics. This was a significant high 00:12:51.409 --> 00:12:54.669 -stakes purchase. It cost $21 billion. $21 billion. 00:12:54.870 --> 00:12:57.529 And the key asset here was ibrutinib, or Imbruvica, 00:12:57.750 --> 00:12:59.610 a highly valuable treatment for blood cancers. 00:12:59.970 --> 00:13:02.549 This acquisition was foundational for their oncology 00:13:02.549 --> 00:13:05.009 portfolio. It instantly made them a major player 00:13:05.009 --> 00:13:07.629 in the space. What's fascinating about that $21 00:13:07.629 --> 00:13:11.500 billion deal is that it wasn't an easy win. The 00:13:11.500 --> 00:13:14.139 sources show that AstraZeneca was also bidding 00:13:14.139 --> 00:13:17.779 fiercely for pharmacyclics. Bidding more. Exactly. 00:13:17.940 --> 00:13:20.600 And that tells you two things. First, AbbVie 00:13:20.600 --> 00:13:22.820 was willing to pay a massive premium to secure 00:13:22.820 --> 00:13:26.059 a proven asset. And second, there's fierce high 00:13:26.059 --> 00:13:28.320 -stakes competition among the largest pharmaceutical 00:13:28.320 --> 00:13:31.460 firms for late -stage oncology drugs because 00:13:31.460 --> 00:13:33.639 the margins are just so high. And they doubled 00:13:33.639 --> 00:13:37.179 down on oncology a year later. In 2016, AbbVie 00:13:37.179 --> 00:13:40.460 acquired StemCentrics for up to $9 .8 billion. 00:13:40.490 --> 00:13:44.509 This signaled a clear, sustained, and relentless 00:13:44.509 --> 00:13:47.129 commitment to building a major presence in cancer 00:13:47.129 --> 00:13:49.149 treatment. So they spent huge amounts of capital. 00:13:49.250 --> 00:13:52.750 Almost $31 billion in two years just on oncology 00:13:52.750 --> 00:13:55.309 acquisitions, all to rapidly establish expertise 00:13:55.309 --> 00:13:57.870 and market share in this critical field. But 00:13:57.870 --> 00:14:00.029 the single most transformative moment in Abbott's 00:14:00.029 --> 00:14:02.070 corporate life, outside of the original Abbott 00:14:02.070 --> 00:14:05.110 spinoff, has to be the 2019 acquisition of Allergan 00:14:05.110 --> 00:14:07.360 Place. I mean, this deal was truly enormous. 00:14:08.019 --> 00:14:11.899 $63 billion. $63 billion. That is a colossal 00:14:11.899 --> 00:14:15.240 number. And it immediately brought the full weight 00:14:15.240 --> 00:14:18.179 of Allergan's portfolio, including that Botox 00:14:18.179 --> 00:14:20.299 powerhouse, right into the AbbVie structure. 00:14:20.580 --> 00:14:24.620 A $63 billion acquisition is highly leveraged. 00:14:24.679 --> 00:14:27.879 It comes with significant debt. It's an enormous 00:14:27.879 --> 00:14:30.559 logistical undertaking. But it achieved the crucial 00:14:30.559 --> 00:14:34.279 strategic goal. Immediate. massive diversification 00:14:34.279 --> 00:14:36.799 outside of the autoimmune field, making them 00:14:36.799 --> 00:14:39.539 less reliant on the success of the humerus successors. 00:14:39.659 --> 00:14:42.779 It transformed them overnight into a leader in 00:14:42.779 --> 00:14:45.299 aesthetics and several neuroscience segments. 00:14:45.600 --> 00:14:48.279 That transaction was complex, especially given 00:14:48.279 --> 00:14:50.860 where Allergan was based. Allergan was Irish, 00:14:51.039 --> 00:14:53.179 and this naturally raised questions about using 00:14:53.179 --> 00:14:55.740 M &A for tax strategy. But the sources confirmed 00:14:55.740 --> 00:14:57.919 that this deal was not structured as a tax inversion. 00:14:58.659 --> 00:15:01.259 Avi remained legally domiciled in the U .S. for 00:15:01.259 --> 00:15:03.299 tax purposes. And it's important to understand 00:15:03.299 --> 00:15:05.639 why they didn't pursue a tax inversion in 2019, 00:15:05.799 --> 00:15:07.899 because they certainly tried before. But first, 00:15:08.000 --> 00:15:09.960 let's talk about the MTC requirement for the 00:15:09.960 --> 00:15:12.899 Allergan deal. The divestitures. Right. To gain 00:15:12.899 --> 00:15:14.879 approval from the Federal Trade Commission, they 00:15:14.879 --> 00:15:17.559 had to make some key divestitures, meaning they 00:15:17.559 --> 00:15:19.679 had to sell off certain assets to prevent market 00:15:19.679 --> 00:15:22.480 concentration. They sold the gastrointestinal 00:15:22.480 --> 00:15:25.960 candidate Brazikumab to AstraZeneca and the pancreatic 00:15:25.960 --> 00:15:30.000 enzymes Zenpep and Viocash to Nestle. The government 00:15:30.000 --> 00:15:32.240 wanted to make sure the merged entity wasn't 00:15:32.240 --> 00:15:34.460 creating monopolies in specific drug classes. 00:15:34.720 --> 00:15:37.039 That divestiture requirement really highlights 00:15:37.039 --> 00:15:39.399 just how thoroughly the government monitors these 00:15:39.399 --> 00:15:41.899 mega deals. But let's circle back to that earlier. 00:15:41.929 --> 00:15:43.850 Earlier, a failure you mentioned, the attempted 00:15:43.850 --> 00:15:46.870 tax inversion. Yes, the attempt to acquire Shire 00:15:46.870 --> 00:15:50.529 in 2014. This deal was explicitly aiming to be 00:15:50.529 --> 00:15:52.549 one of the largest tax inversions in history. 00:15:52.690 --> 00:15:54.889 The whole plan was for the company to legally 00:15:54.889 --> 00:15:57.789 change its tax domicile from the high tax U .S. 00:15:57.789 --> 00:16:00.250 to the lower tax jurisdiction of Shire, which 00:16:00.250 --> 00:16:02.809 is based in Ireland. It was a popular, though, 00:16:02.909 --> 00:16:05.370 very controversial corporate strategy at the 00:16:05.370 --> 00:16:07.870 time. And that attempt failed spectacularly. 00:16:07.870 --> 00:16:10.710 Why? What specifically doomed that massive transaction? 00:16:11.279 --> 00:16:13.759 It was a direct consequence of policy. The US 00:16:13.759 --> 00:16:15.799 Treasury Department, under a lot of pressure 00:16:15.799 --> 00:16:18.259 to curb corporate inversions, introduced new 00:16:18.259 --> 00:16:21.139 rules that significantly restricted the tax benefits 00:16:21.139 --> 00:16:23.899 you could get from these deals. These changes 00:16:23.899 --> 00:16:26.639 were aimed at making it impossible for a US company 00:16:26.639 --> 00:16:29.039 to acquire a foreign company, shift its legal 00:16:29.039 --> 00:16:32.440 address, and still retain major access to its 00:16:32.440 --> 00:16:35.399 overseas capital without paying US taxes on it. 00:16:35.769 --> 00:16:38.830 So the financial logic just evaporated. It completely 00:16:38.830 --> 00:16:41.409 undermined the logic of the deal, so AbbVie pulled 00:16:41.409 --> 00:16:43.549 out. And the financial consequence of this termination 00:16:43.549 --> 00:16:46.629 was not minor. They were forced to pay a substantial 00:16:46.629 --> 00:16:50.970 $1 .6 billion breakup fee to Shire. A billion 00:16:50.970 --> 00:16:53.289 and a half dollars. That is a staggering penalty. 00:16:53.529 --> 00:16:55.389 That kind of penalty could cripple a smaller 00:16:55.389 --> 00:16:58.889 company or entirely derail a midsize one. How 00:16:58.889 --> 00:17:01.389 did AbbVie, a newly formed company at the time, 00:17:01.529 --> 00:17:04.470 absorb that kind of loss without derailing their 00:17:04.470 --> 00:17:07.089 whole M &A strategy? It just shows the sheer 00:17:07.089 --> 00:17:09.109 scale of the financial reserves they maintained, 00:17:09.490 --> 00:17:11.970 which were largely driven by those colossal Humira 00:17:11.970 --> 00:17:16.069 revenues. While $1 .6 billion is immense, in 00:17:16.069 --> 00:17:18.769 the context of a company projecting tens of billions 00:17:18.769 --> 00:17:21.529 in annual revenue, it was treated as an expensive 00:17:21.529 --> 00:17:24.089 strategic misstep, not an existential threat. 00:17:24.349 --> 00:17:27.099 So they learned their lesson. They did. Don't 00:17:27.099 --> 00:17:29.619 rely on the tax inversion structure. Instead, 00:17:29.759 --> 00:17:31.920 they focused on growth through pure acquisition, 00:17:32.220 --> 00:17:35.279 accepting the U .S. domicile. But as we'll see 00:17:35.279 --> 00:17:37.039 in Section 4, they found other sophisticated 00:17:37.039 --> 00:17:39.740 ways to manage their tax liability. The lesson 00:17:39.740 --> 00:17:42.160 was clearly learned. And the M &A model hasn't 00:17:42.160 --> 00:17:44.099 slowed down, especially as they look to secure 00:17:44.099 --> 00:17:46.440 the next generation of revenue streams post Humira. 00:17:47.110 --> 00:17:49.670 We've seen a rapid late -stage growth spree in 00:17:49.670 --> 00:17:52.869 the 2024 and 2025 timeframe, focused heavily 00:17:52.869 --> 00:17:55.069 on securing dominance in oncology and neuroscience. 00:17:55.529 --> 00:17:57.670 Let's break that recent spree down. In February 00:17:57.670 --> 00:18:00.970 2024, they acquired Immunogen for $10 .1 billion. 00:18:01.849 --> 00:18:04.930 The goal here was very specific. Expedite entry 00:18:04.930 --> 00:18:07.410 into the ovarian cancer treatment market via 00:18:07.410 --> 00:18:10.769 Immunogen's key drug, Elihir. This drug is critically 00:18:10.769 --> 00:18:13.650 important because it's an ADC and antibody drug 00:18:13.650 --> 00:18:15.890 conjugate. That sounds like highly specialized 00:18:15.890 --> 00:18:18.349 technology. Okay, can you quickly break down 00:18:18.349 --> 00:18:21.170 what an ADC is and why it commands a $10 billion 00:18:21.170 --> 00:18:25.549 price tag? Certainly. Think of an ADC as a molecular 00:18:25.549 --> 00:18:28.170 guided missile. It combines three components. 00:18:28.549 --> 00:18:31.109 A monoclonal antibody, which is the guidance 00:18:31.109 --> 00:18:33.509 system, and it specifically recognizes and binds 00:18:33.509 --> 00:18:36.049 to a unique marker on a cancer cell. It's a target. 00:18:36.289 --> 00:18:38.609 Highly targeted. Then there's a toxic chemical 00:18:38.609 --> 00:18:41.650 payload, the warhead, and a linker that holds 00:18:41.650 --> 00:18:43.369 the two together until they reach the target. 00:18:43.769 --> 00:18:45.970 The huge advantage is that it delivers the highly 00:18:45.970 --> 00:18:48.529 toxic chemotherapy directly to the cancer cell, 00:18:48.690 --> 00:18:51.589 sparing healthy tissue and reducing those debilitating 00:18:51.589 --> 00:18:54.990 side effects. Acquiring a successful ADC platform 00:18:54.990 --> 00:18:57.950 like Immunogen instantly gives AbbVie cutting 00:18:57.950 --> 00:19:00.529 -edge technology and a major market share in 00:19:00.529 --> 00:19:03.029 targeted cancer therapy. So after securing that 00:19:03.029 --> 00:19:05.609 oncology asset, they pivoted hard to neuroscience, 00:19:05.990 --> 00:19:08.670 really confirming their commitment to the pipeline 00:19:08.670 --> 00:19:11.849 they built with Allergan. Precisely. In August 00:19:11.849 --> 00:19:15.049 2024, They acquired Cerevel Therapeutics for 00:19:15.049 --> 00:19:18.670 $8 .7 billion, specifically to expand the drug 00:19:18.670 --> 00:19:21.390 pipeline in neurological conditions. Just two 00:19:21.390 --> 00:19:24.589 months later, in October 2024, they followed 00:19:24.589 --> 00:19:26.809 up with the acquisition of Aliata Therapeutics 00:19:26.809 --> 00:19:30.069 for $1 .4 billion, further boosting that neuroscience 00:19:30.069 --> 00:19:32.630 pipeline. So big back -to -back deals. This quick 00:19:32.630 --> 00:19:35.230 succession shows a deliberate, urgent effort 00:19:35.230 --> 00:19:37.730 to establish a dominant position in treating 00:19:37.730 --> 00:19:40.150 neurological conditions, knowing that this field 00:19:40.150 --> 00:19:42.849 represents enormous future growth. they're still 00:19:42.849 --> 00:19:44.869 fine tuning the foundational autoimmune space. 00:19:45.170 --> 00:19:48.930 In January 2025, they acquired Nimble Therapeutics, 00:19:49.029 --> 00:19:52.130 a Roche spinout focusing on oral peptide treatments 00:19:52.130 --> 00:19:55.490 in the autoimmune area for $200 million. And 00:19:55.490 --> 00:19:57.529 that acquisition, though it's smaller in scale 00:19:57.529 --> 00:19:59.410 than the others, it demonstrates their continued 00:19:59.410 --> 00:20:01.490 interest in next generation therapies for their 00:20:01.490 --> 00:20:03.970 founding therapeutic area using next generation 00:20:03.970 --> 00:20:07.009 delivery methods like oral peptides. What's critical 00:20:07.009 --> 00:20:09.670 for you, the listener, to understand is the sheer 00:20:09.670 --> 00:20:12.460 corporate complexity that's inherited through 00:20:12.460 --> 00:20:14.940 these rapid fire deals. The acquisition history 00:20:14.940 --> 00:20:18.099 chart in the sources shows that when AbbVie acquired 00:20:18.099 --> 00:20:20.400 Allergan, they didn't just buy a company. No, 00:20:20.500 --> 00:20:22.619 they bought a deep stack of corporate history. 00:20:22.880 --> 00:20:25.000 Allergan itself was the result of numerous prior 00:20:25.000 --> 00:20:27.880 acquisitions. Activists, Forest Laboratories, 00:20:28.059 --> 00:20:31.420 Kithara, Furex Pharmaceuticals, dozens of others. 00:20:31.599 --> 00:20:34.289 They became the ultimate corporate curator. They 00:20:34.289 --> 00:20:36.470 were suddenly responsible for managing the legal, 00:20:36.529 --> 00:20:39.990 the regulatory, and the R &D legacies of companies 00:20:39.990 --> 00:20:42.710 like Forest Laboratories, which had itself acquired 00:20:42.710 --> 00:20:45.190 Aptos Pharma and Axcan Pharma. It means their 00:20:45.190 --> 00:20:48.009 M &A model is less about internal peer discovery 00:20:48.009 --> 00:20:51.130 and more about integrating vast, complex networks 00:20:51.130 --> 00:20:54.170 of pharmaceutical assets. It means their balance 00:20:54.170 --> 00:20:56.289 sheet now carries not only the potential of future 00:20:56.289 --> 00:20:58.990 drugs, but also the historical liabilities of 00:20:58.990 --> 00:21:01.059 the companies they swallowed whole. It's clear 00:21:01.059 --> 00:21:03.559 that M &A is the primary engine for scaling assets. 00:21:03.920 --> 00:21:06.079 But what about the foundational research? That 00:21:06.079 --> 00:21:08.660 can't all be bought. The sources indicate AbbVie 00:21:08.660 --> 00:21:10.880 runs a parallel strategy focused on external 00:21:10.880 --> 00:21:13.619 collaborations. That's right. While the M &A 00:21:13.619 --> 00:21:16.059 strategy is about securing existing assets and 00:21:16.059 --> 00:21:19.039 proven revenue, AbbVie also relies heavily on 00:21:19.039 --> 00:21:21.480 external partnerships to drive basic research 00:21:21.480 --> 00:21:24.099 and spread the immense financial risk of early 00:21:24.099 --> 00:21:27.279 stage discovery. It's a key tactic. collaborate 00:21:27.279 --> 00:21:29.700 with niche experts or specialized platforms, 00:21:30.000 --> 00:21:32.640 allowing AbbVie to tap into bleeding -edge science 00:21:32.640 --> 00:21:34.839 without having to develop the foundational technology 00:21:34.839 --> 00:21:37.900 internally. A compelling example of this is their 00:21:37.900 --> 00:21:41.460 2014 R &D collaboration with Calico, which is 00:21:41.460 --> 00:21:44.799 an Alphabet Inc. subsidiary. The focus was incredibly 00:21:44.799 --> 00:21:47.519 ambitious, almost futuristic. Yeah, developing 00:21:47.519 --> 00:21:49.920 new therapies for aging -associated diseases, 00:21:50.319 --> 00:21:53.460 including neurodegeneration and cancer. That 00:21:53.460 --> 00:21:56.200 partnership highlights a massive, long -term, 00:21:56.299 --> 00:21:58.599 high -risk, high -reward bet on the fundamental 00:21:58.599 --> 00:22:01.539 biology of aging. It shows they are willing to 00:22:01.539 --> 00:22:03.880 put capital into fundamental science that may 00:22:03.880 --> 00:22:06.519 not yield a drug for 20 years, but if it does, 00:22:06.640 --> 00:22:09.119 the societal and market impact would be, well, 00:22:09.220 --> 00:22:11.220 transformative. It's the kind of research that 00:22:11.220 --> 00:22:13.579 traditional internal R &D offers. struggles to 00:22:13.579 --> 00:22:15.980 prioritize because of quarterly pressures. They 00:22:15.980 --> 00:22:19.000 also utilize specialized collaborations to bolster 00:22:19.000 --> 00:22:21.480 their pipeline in existing areas in very novel 00:22:21.480 --> 00:22:25.779 ways. In 2016, they entered a multi -year R &D 00:22:25.779 --> 00:22:28.900 collaboration with Synlogic, a synthetic biology 00:22:28.900 --> 00:22:31.140 company. This was built on research from MIT. 00:22:31.400 --> 00:22:34.339 Right. And Abby secured worldwide rights to Synlogix 00:22:34.339 --> 00:22:37.059 probiotic based technology for treating inflammatory 00:22:37.059 --> 00:22:40.720 bowel disease or IBD, specifically Crohn's and 00:22:40.720 --> 00:22:43.279 ulcerative colitis. And that is fascinating because 00:22:43.279 --> 00:22:45.500 they are looking beyond traditional chemical 00:22:45.500 --> 00:22:48.960 compounds. Synlogix technology involves engineering 00:22:48.960 --> 00:22:51.579 probiotics, essentially designing bacteria that 00:22:51.579 --> 00:22:54.059 live in the gut to deliver or produce therapeutic 00:22:54.059 --> 00:22:56.299 molecules directly at the site of inflammation. 00:22:56.720 --> 00:22:59.480 It's a commitment to exploring biological platform 00:22:59.480 --> 00:23:01.799 technologies, not just small molecules. or antibodies, 00:23:02.099 --> 00:23:03.980 it shows a really sophisticated understanding 00:23:03.980 --> 00:23:06.500 of future therapeutic modalities. And staying 00:23:06.500 --> 00:23:09.059 on that theme, in April 2016, they expanded a 00:23:09.059 --> 00:23:12.259 cystic fibrosis deal with Galapagos NV, potentially 00:23:12.259 --> 00:23:14.480 doubling milestone payments to $600 million. 00:23:15.099 --> 00:23:17.299 This highlights their dedication to therapeutic 00:23:17.299 --> 00:23:20.500 areas, even when market competition like Vertex's 00:23:20.500 --> 00:23:23.220 strong domination of the CF field is incredibly 00:23:23.220 --> 00:23:25.619 intense. They are betting on technological superiority 00:23:25.619 --> 00:23:28.599 to capture market share. And we see this collaborative 00:23:28.599 --> 00:23:30.799 effort repeated across their oncology. portfolio, 00:23:31.079 --> 00:23:33.359 too. They partnered with the University of Chicago 00:23:33.359 --> 00:23:36.420 in 2016 to investigate several specific areas 00:23:36.420 --> 00:23:39.119 of oncology, and they entered co -commercialization 00:23:39.119 --> 00:23:43.400 deals for immunotherapies like ARGENTA's ARGX115. 00:23:43.680 --> 00:23:46.519 These are all ways to access specialized biological 00:23:46.519 --> 00:23:49.279 mechanisms being developed by smaller, nimble 00:23:49.279 --> 00:23:51.559 firms. What's truly exciting, though, is how 00:23:51.559 --> 00:23:54.119 these collaborations have shifted recently. They 00:23:54.119 --> 00:23:56.559 reflect the absolute cutting edge of drug discovery 00:23:56.559 --> 00:23:59.660 moving from just buying specific late -stage 00:23:59.660 --> 00:24:02.490 drugs drugs to investing heavily in next generation 00:24:02.490 --> 00:24:06.289 platforms. The 2024 and 2025 partnerships reveal 00:24:06.289 --> 00:24:09.230 a strong focus on new modalities that are reshaping 00:24:09.230 --> 00:24:12.369 the industry. In February 2024, they initiated 00:24:12.369 --> 00:24:15.609 a long -term collaboration with Tenterix Biotherapeutics. 00:24:15.710 --> 00:24:18.190 This is focused on multi -specific biological 00:24:18.190 --> 00:24:21.569 candidates in oncology and immunology using their 00:24:21.569 --> 00:24:23.470 patented tentacles platform. So they're hitting 00:24:23.470 --> 00:24:25.930 multiple targets at once. Exactly. And then in 00:24:25.930 --> 00:24:28.809 January 2025, they announced a colossal one - 00:24:34.190 --> 00:24:36.990 Okay, you've got to unpack that for me. Molecular 00:24:36.990 --> 00:24:38.910 glutegraders sounds like something out of science 00:24:38.910 --> 00:24:41.910 fiction. Why is this mechanism attracting such 00:24:41.910 --> 00:24:44.730 massive investment? That's where the aha moment 00:24:44.730 --> 00:24:47.529 is. Historically, drugs worked by blocking a 00:24:47.529 --> 00:24:50.529 bad protein. Think of a cork in a bottle. Molecular 00:24:50.529 --> 00:24:53.720 glutegraders flip that script entirely. They 00:24:53.720 --> 00:24:56.000 don't block the protein. They trigger the cell's 00:24:56.000 --> 00:24:58.440 natural waste disposal system, the proteasome, 00:24:58.559 --> 00:25:01.299 to destroy the unwanted protein. So it's not 00:25:01.299 --> 00:25:03.920 blocking, it's removing. It's removing it completely. 00:25:04.180 --> 00:25:07.940 The drug acts as the glue that attaches the bad 00:25:07.940 --> 00:25:10.319 protein to the machinery that marks it for destruction. 00:25:11.130 --> 00:25:13.450 It's a fundamental shift in how we approach drug 00:25:13.450 --> 00:25:15.970 targets, and it allows researchers to tackle 00:25:15.970 --> 00:25:19.829 previously undruggable proteins. This partnership, 00:25:19.930 --> 00:25:23.589 at $1 .64 billion, represents a massive financial 00:25:23.589 --> 00:25:26.069 commitment to a very modern mechanism of action. 00:25:26.269 --> 00:25:28.589 That explanation makes the investment instantly 00:25:28.589 --> 00:25:30.890 understandable. You're not just buying a drug, 00:25:30.970 --> 00:25:33.049 you're buying a platform that can potentially 00:25:33.049 --> 00:25:35.740 develop hundreds of new drugs. And this forward 00:25:35.740 --> 00:25:39.259 -looking investment continued in May 2025, when 00:25:39.259 --> 00:25:41.500 they entered a deal with Adarx Pharmaceuticals 00:25:41.500 --> 00:25:44.519 to develop a new type of RNA technology for neuroscience, 00:25:45.000 --> 00:25:47.920 immunology, and oncology. This points toward 00:25:47.920 --> 00:25:50.299 the next wave of therapeutics following the success 00:25:50.299 --> 00:25:53.920 of mRNA vaccines. These three recent deals, Tenterix, 00:25:54.119 --> 00:25:56.980 Neomorph, and Adarx, show that the strategy is 00:25:56.980 --> 00:25:59.359 evolving beyond buying the finished blockbuster 00:25:59.359 --> 00:26:02.019 to buying the underlying technology that can 00:26:02.019 --> 00:26:04.059 engineer the next generation of blockbusters. 00:26:04.319 --> 00:26:06.299 It mitigates the risk of internal failure by 00:26:06.299 --> 00:26:08.640 spreading R &D capital across multiple specialized 00:26:08.640 --> 00:26:11.420 external platforms. Before we move on to the 00:26:11.420 --> 00:26:13.740 legal challenges, we have to look at one interesting 00:26:13.740 --> 00:26:16.710 case study from the COVID -19 pandemic. involving 00:26:16.710 --> 00:26:20.210 their infectious disease drugs. In March 2020, 00:26:20.549 --> 00:26:23.089 AbbVie announced plans to evaluate its HIV medicine, 00:26:23.329 --> 00:26:25.609 Colectra, as a possible COVID -19 treatment, 00:26:25.849 --> 00:26:28.109 quickly partnering with health authorities across 00:26:28.109 --> 00:26:30.130 different countries to investigate its efficacy. 00:26:30.640 --> 00:26:33.200 Ultimately, the first non -blinded, randomized 00:26:33.200 --> 00:26:36.279 trial found that Coletra was not useful for treating 00:26:36.279 --> 00:26:39.200 severe COVID -19 in hospitalized patients, which 00:26:39.200 --> 00:26:41.519 was a critical scientific finding at the time. 00:26:41.579 --> 00:26:44.599 It helped focus global research efforts elsewhere. 00:26:44.880 --> 00:26:48.119 But the situation raised a fascinating high -stakes 00:26:48.119 --> 00:26:50.299 conflict regarding intellectual property and 00:26:50.299 --> 00:26:53.440 public health. It really did. As the global crisis 00:26:53.440 --> 00:26:56.240 intensified, there was immense political pressure 00:26:56.240 --> 00:26:58.720 regarding access to any potentially useful drug. 00:26:59.069 --> 00:27:01.150 The Israeli government, citing the health crisis, 00:27:01.369 --> 00:27:03.890 announced that it would force AbbVie to license 00:27:03.890 --> 00:27:06.549 its patents for Coletra under compulsory licensing 00:27:06.549 --> 00:27:09.630 rules. In response to this global pressure, AbbVie 00:27:09.630 --> 00:27:11.849 made a highly notable and strategic decision. 00:27:12.190 --> 00:27:14.430 They announced they would cease enforcing their 00:27:14.430 --> 00:27:17.210 patents on Coletra entirely across the globe 00:27:17.210 --> 00:27:19.309 for the duration of the pandemic. That's a huge 00:27:19.309 --> 00:27:23.200 move. It's a huge move. And that decision, though 00:27:23.200 --> 00:27:25.400 specific to that drug and that global health 00:27:25.400 --> 00:27:28.160 emergency, provides a fascinating glimpse into 00:27:28.160 --> 00:27:30.180 the inherent tensions between intellectual property 00:27:30.180 --> 00:27:33.440 protection, which incentivizes R &D, and urgent 00:27:33.440 --> 00:27:36.220 public need, which demands widespread access. 00:27:36.539 --> 00:27:38.619 It was a very high profile demonstration of corporate 00:27:38.619 --> 00:27:42.000 responsibility. maybe spurred by political necessity. 00:27:42.279 --> 00:27:44.859 But it was a moment where the IP wall came down 00:27:44.859 --> 00:27:47.779 globally for that specific drug. We've established 00:27:47.779 --> 00:27:49.900 that AbbVie is a financial and M &A machine. 00:27:50.380 --> 00:27:52.779 But the flip side of operating at this scale 00:27:52.779 --> 00:27:56.640 is the intense, continuous legal scrutiny. The 00:27:56.640 --> 00:27:58.619 financial successes we discussed in Section 1 00:27:58.619 --> 00:28:01.440 and the aggressive M &A in Section 2 are, you 00:28:01.440 --> 00:28:03.119 know, they're inseparable from the allegations 00:28:03.119 --> 00:28:05.160 and settlements detail in the sources you provided. 00:28:05.440 --> 00:28:07.819 For a company operating at this scale, the legal 00:28:07.819 --> 00:28:10.359 landscape is vast and complex. It often focuses 00:28:10.359 --> 00:28:12.299 on how they maintain market dominance and how 00:28:12.299 --> 00:28:15.019 they manage pricing and taxation. Let's start 00:28:15.019 --> 00:28:17.180 with market control, which is absolutely crucial 00:28:17.180 --> 00:28:20.740 for maximizing revenue from a drug like the original 00:28:20.740 --> 00:28:23.539 Humira. Abbey has faced significant accusations 00:28:23.539 --> 00:28:26.940 of using anti -competitive practices, often involving 00:28:26.940 --> 00:28:29.579 the creation of what the sources call patent 00:28:29.579 --> 00:28:31.960 thickets. I want to break down that concept of 00:28:31.960 --> 00:28:34.200 a patent thicket. It sounds like an intentional 00:28:34.200 --> 00:28:37.509 legal... minefield, how does it work specifically 00:28:37.509 --> 00:28:40.440 to block competitors? That's exactly what it 00:28:40.440 --> 00:28:43.039 is. A patent thicket involves creating a dense 00:28:43.039 --> 00:28:46.480 web of secondary patents, not just on the primary 00:28:46.480 --> 00:28:49.819 molecule, but on hundreds of small details. The 00:28:49.819 --> 00:28:52.640 formulation, the specific dosing regimen, the 00:28:52.640 --> 00:28:54.859 injection pen device, the storage temperature. 00:28:55.220 --> 00:28:57.740 Everything. Everything. The accusation is that 00:28:57.740 --> 00:29:00.099 this is done primarily to complicate and slow 00:29:00.099 --> 00:29:03.039 down the process for potentially cheaper biosimilars 00:29:03.039 --> 00:29:05.559 from entering the market, thus extending the 00:29:05.559 --> 00:29:07.599 monopoly well beyond the life of the primary 00:29:07.599 --> 00:29:10.789 drug patent. So a potential biosimilar developer 00:29:10.789 --> 00:29:12.869 might be able to easily replicate the main molecule, 00:29:13.089 --> 00:29:15.910 but then they have to navigate or challenge dozens 00:29:15.910 --> 00:29:18.170 of separate patents on the device or the formulation. 00:29:18.190 --> 00:29:21.529 Which often results in years of expensive, complex 00:29:21.529 --> 00:29:24.650 litigation. It makes the prospect of entering 00:29:24.650 --> 00:29:27.029 the market incredibly unattractive. That's the 00:29:27.029 --> 00:29:30.529 strategic goal. The sources confirm that AbbVie 00:29:30.529 --> 00:29:33.269 and a competitor, Alvotech, filed mutual lawsuits 00:29:33.269 --> 00:29:36.609 regarding a Humira biosimilar. This patent fight 00:29:36.609 --> 00:29:38.890 was eventually settled out of court in 2022, 00:29:39.250 --> 00:29:42.450 but the underlined strategy of aggressive patent 00:29:42.450 --> 00:29:44.710 defense remains a defining characteristic of 00:29:44.710 --> 00:29:47.250 protecting their high -value assets. It buys 00:29:47.250 --> 00:29:50.170 them years of continued, uninhibited revenue. 00:29:50.589 --> 00:29:53.150 And this issue isn't unique to Humira either. 00:29:53.680 --> 00:29:56.160 Forrest Laboratories, that subsidiary acquired 00:29:56.160 --> 00:29:59.359 during the M &A spree, was accused of using unlawful 00:29:59.359 --> 00:30:01.839 deals to prevent generic versions of its Alzheimer's 00:30:01.839 --> 00:30:04.019 drug, Namenda, from entering the market. And 00:30:04.019 --> 00:30:06.240 that litigation persists across their acquired 00:30:06.240 --> 00:30:08.799 portfolios, demonstrating the inherent risk of 00:30:08.799 --> 00:30:11.180 integrating the past legal liabilities of acquired 00:30:11.180 --> 00:30:13.559 companies. Beyond direct competition, they've 00:30:13.559 --> 00:30:15.799 also faced allegations regarding marketing tactics, 00:30:16.019 --> 00:30:19.700 specifically involving kickbacks. In 2018, AbbVie 00:30:19.700 --> 00:30:22.299 agreed to pay $25 million to resolve allegations 00:30:22.299 --> 00:30:27.529 that they used kickbacks. And perhaps more controversially, 00:30:27.589 --> 00:30:30.690 in 2020, they agreed to pay $24 million to resolve 00:30:30.690 --> 00:30:33.009 allegations of kickback schemes specifically 00:30:33.009 --> 00:30:36.069 used to promote Humira using nurse ambassadors. 00:30:36.650 --> 00:30:39.109 That term nurse ambassador sounds insidious. 00:30:39.210 --> 00:30:41.430 Can you explain what the sources detailed about 00:30:41.430 --> 00:30:43.809 how they allegedly used trusted medical professionals 00:30:43.809 --> 00:30:47.369 to steer patients toward the branded drug? It 00:30:47.369 --> 00:30:50.250 speaks to a profound issue of trust. The allegation 00:30:50.250 --> 00:30:52.490 was that these highly trained ambassadors, often 00:30:52.490 --> 00:30:55.269 registered nurses, were positioned as impartial 00:30:55.269 --> 00:30:57.950 patient support figures, helping patients learn 00:30:57.950 --> 00:31:00.349 how to inject the drug, managing side effects, 00:31:00.430 --> 00:31:03.069 and so on. However, they were allegedly used 00:31:03.069 --> 00:31:05.869 as marketers, advising patients away from alternatives 00:31:05.869 --> 00:31:08.789 and toward the branded AbbVie drug in exchange 00:31:08.789 --> 00:31:11.849 for kickbacks. The California insurance chief 00:31:11.849 --> 00:31:14.150 at the time described this as a far -reaching 00:31:14.150 --> 00:31:16.529 scheme where trusted medical professionals were 00:31:16.529 --> 00:31:18.890 allegedly co -opted to maintain blockbuster sales. 00:31:18.920 --> 00:31:21.460 While the company settled these claims without 00:31:21.460 --> 00:31:23.900 admitting wrongdoing, these practices highlight 00:31:23.900 --> 00:31:26.319 the aggressive, sometimes ethically questionable 00:31:26.319 --> 00:31:37.559 lengths taken to protect their sales. pursued 00:31:37.559 --> 00:31:41.299 a variety of tactics to increase drug sales while 00:31:41.299 --> 00:31:44.440 raising prices for Americans, specifically pointing 00:31:44.440 --> 00:31:46.960 to the exploitation of the patent system, which 00:31:46.960 --> 00:31:49.720 we just discussed, and the abuse of orphan drug 00:31:49.720 --> 00:31:52.740 protections to block competition. And that congressional 00:31:52.740 --> 00:31:55.640 scrutiny has tangible real -world consequences, 00:31:56.180 --> 00:31:59.200 particularly due to the mechanisms of the Inflation 00:31:59.200 --> 00:32:02.839 Reduction Act, or IRA. As a direct result of 00:32:02.839 --> 00:32:05.180 these negotiation mechanisms designed to lower 00:32:05.180 --> 00:32:08.039 drug prices for Medicare, the price of Imbruvica, 00:32:08.299 --> 00:32:10.680 one of their major oncology drugs, was reduced 00:32:10.680 --> 00:32:15.640 by 38 % to $9 ,319 per month, effective in 2026. 00:32:15.980 --> 00:32:18.680 A 38 % reduction. Yeah, this demonstrates the 00:32:18.680 --> 00:32:20.839 government's increasing ability to exert downward 00:32:20.839 --> 00:32:23.059 pressure on the high costs that the House Oversight 00:32:23.059 --> 00:32:25.660 Committee identified. Now, let's tackle the taxation 00:32:25.660 --> 00:32:27.880 strategies, which are particularly startling 00:32:27.880 --> 00:32:29.960 and perhaps the most complex area of scrutiny. 00:32:30.460 --> 00:32:33.960 In 2021, the US Senate Finance Committee began 00:32:33.960 --> 00:32:36.140 an investigation to determine if the company 00:32:36.140 --> 00:32:38.420 was taking advantage of loopholes in the 2017 00:32:38.420 --> 00:32:41.539 Tax Cuts and Jobs Act to significantly reduce 00:32:41.539 --> 00:32:45.000 its US tax liability. The report, released in 00:32:45.000 --> 00:32:48.599 July 2022, detailed the mechanism that facilitated 00:32:48.599 --> 00:32:51.599 this reduction. AbbVie was able to avoid U .S. 00:32:51.619 --> 00:32:54.259 taxes by registering intellectual property, the 00:32:54.259 --> 00:32:57.099 source of massive revenue, in offshore jurisdictions 00:32:57.099 --> 00:32:59.920 like Bermuda. So the profits don't even register 00:32:59.920 --> 00:33:02.180 in the U .S.? It involves sophisticated internal 00:33:02.180 --> 00:33:04.880 transfer pricing schemes where the U .S. entity 00:33:04.880 --> 00:33:07.599 effectively pays its Bermuda IP holding company 00:33:07.599 --> 00:33:09.839 immense royalties for the right to sell the drugs 00:33:09.839 --> 00:33:12.039 in the U .S. And the sources provide a shocking 00:33:12.039 --> 00:33:15.200 ratio. Wait, so despite receiving 75 % of its 00:33:15.200 --> 00:33:17.500 sales of Humira in the United States, the Senate 00:33:17.500 --> 00:33:20.079 report found that Abby reported only 1 % of that 00:33:20.079 --> 00:33:23.200 income for U .S. tax purposes in 2020. Run that 00:33:23.200 --> 00:33:26.180 by me again. You heard it right. 75 % of sales 00:33:26.180 --> 00:33:29.319 in the U .S., but they reported only 1 % of that 00:33:29.319 --> 00:33:33.119 income for U .S. tax purposes. It is a stunning 00:33:33.119 --> 00:33:36.640 figure that illustrates the core issue. By channeling 00:33:36.640 --> 00:33:38.880 the profits derived from U .S. sales through 00:33:38.880 --> 00:33:41.940 offshore IP holdings, the company reported a 00:33:41.940 --> 00:33:45.880 $4 .5 billion pre -tax loss in the U .S. that 00:33:45.880 --> 00:33:49.359 year. A loss. A loss, while simultaneously recording 00:33:49.359 --> 00:33:53.059 $7 .9 billion in overseas pre -tax profit. The 00:33:53.059 --> 00:33:54.940 report estimated that this strategy resulted 00:33:54.940 --> 00:33:57.900 in AbbVie avoiding approximately $4 .3 billion 00:33:57.900 --> 00:34:01.599 in U .S. taxes in 2020 alone. That's not just 00:34:01.599 --> 00:34:03.740 sophisticated accounting. That feels like a fundamental 00:34:03.740 --> 00:34:06.400 challenge to the U .S. tax structure. It shows 00:34:06.400 --> 00:34:08.960 just how much revenue is at stake when global 00:34:08.960 --> 00:34:11.360 corporations structure their intellectual property 00:34:11.360 --> 00:34:13.780 and financial domiciles strategically. And finally, 00:34:13.780 --> 00:34:15.780 we need to touch on the range of other significant 00:34:15.780 --> 00:34:18.300 litigation they faced, much of it inherited from 00:34:18.300 --> 00:34:21.719 their acquisitions. Most notably, in July 2022, 00:34:22.219 --> 00:34:25.519 the Allergan unit agreed to pay up to $2 .37 00:34:25.519 --> 00:34:29.119 billion to settle U .S. lawsuits related to the 00:34:29.119 --> 00:34:32.059 marketing of opioid analgesics. $2 .37 billion. 00:34:32.539 --> 00:34:35.360 Although Avi denied wrongdoing, the settlement 00:34:35.360 --> 00:34:38.360 amount is huge and it puts into perspective the 00:34:38.360 --> 00:34:41.599 massive hidden liabilities baked into these mega 00:34:41.599 --> 00:34:44.360 acquisitions. That is a stunning financial way 00:34:44.360 --> 00:34:47.000 to inherit. It shows that when you buy a corporate 00:34:47.000 --> 00:34:49.519 history as complex as Allergan's, you are buying 00:34:49.519 --> 00:34:52.340 its past legal battles and public health crises. 00:34:52.579 --> 00:34:54.780 And we see ongoing litigation in other areas, 00:34:54.880 --> 00:34:57.420 too. They had a dispute with the NHS in 2018 00:34:57.420 --> 00:35:00.260 regarding procurement rules for hepatitis C treatments, 00:35:00.519 --> 00:35:03.079 a case that was. ultimately dismissed by a UK 00:35:03.079 --> 00:35:06.860 court in 2019. More recently, in September 2024, 00:35:07.239 --> 00:35:09.579 they filed a lawsuit against a rival, Beijing, 00:35:09.980 --> 00:35:12.360 accusing them of stealing trade secrets related 00:35:12.360 --> 00:35:14.800 to a competing cancer therapy. So it's a comprehensive 00:35:14.800 --> 00:35:16.940 picture of a company fighting relentlessly on 00:35:16.940 --> 00:35:20.099 every front, antitrust, marketing, pricing, taxation, 00:35:20.280 --> 00:35:22.980 and now intellectual property protection to protect 00:35:22.980 --> 00:35:26.260 and expand its $56 billion enterprise. So what 00:35:26.260 --> 00:35:27.980 does this all mean for the future of biomedical 00:35:27.980 --> 00:35:31.510 giants? If we synthesize this deep dive, AbbVie 00:35:31.510 --> 00:35:33.909 is defined by two major interconnected characteristics 00:35:33.909 --> 00:35:36.289 that really set the tone for the modern pharmaceutical 00:35:36.289 --> 00:35:39.809 industry. First, it is a masterclass in strategic 00:35:39.809 --> 00:35:42.610 financial engineering. No question. They successfully 00:35:42.610 --> 00:35:45.469 executed the highest stakes maneuver in the pharma 00:35:45.469 --> 00:35:48.989 world. The transition away from a single defining 00:35:48.989 --> 00:35:53.389 blockbuster Humira, to the new dual powerhouses 00:35:53.389 --> 00:35:56.929 of Skyrizi and Rynvok. And crucially, they complemented 00:35:56.929 --> 00:35:59.489 this internal transition with relentless massive 00:35:59.489 --> 00:36:02.789 M &A activity, rapidly expanding their oncology 00:36:02.789 --> 00:36:05.210 and neuroscience portfolios through targeted 00:36:05.210 --> 00:36:07.710 multi -billion dollar deals for companies like 00:36:07.710 --> 00:36:11.139 Immunogen and Cereval. This strategy ensures 00:36:11.139 --> 00:36:13.500 they have multiple growth engines hedging against 00:36:13.500 --> 00:36:15.940 future patent cliffs by constantly acquiring 00:36:15.940 --> 00:36:19.179 late -stage high -value assets. But the second 00:36:19.179 --> 00:36:21.380 defining characteristic is the intense, continuous 00:36:21.380 --> 00:36:24.000 scrutiny they face. The government, from the 00:36:24.000 --> 00:36:25.539 House Oversight Committee to the Senate Finance 00:36:25.539 --> 00:36:27.940 Committee, has targeted their practices regarding 00:36:27.940 --> 00:36:30.440 market control through those extensive patent 00:36:30.440 --> 00:36:32.880 thickets, aggressive pricing strategies, and 00:36:32.880 --> 00:36:35.019 sophisticated tax avoidance mechanisms involving 00:36:35.019 --> 00:36:38.269 offshore IP registration. The legal and ethical 00:36:38.269 --> 00:36:40.409 challenges are as integral to their operation 00:36:40.409 --> 00:36:42.409 as the development of their life -saving drugs. 00:36:42.670 --> 00:36:45.550 Indeed. And it forces us to consider the implications 00:36:45.550 --> 00:36:48.670 of their chosen growth model, the bulk of their 00:36:48.670 --> 00:36:51.369 new pipeline and future revenue, increasingly 00:36:51.369 --> 00:36:53.670 comes from massive, high -value acquisitions 00:36:53.670 --> 00:36:56.889 of smaller, innovative startups or through strategic 00:36:56.889 --> 00:36:59.269 collaborations with platform developers like 00:36:59.269 --> 00:37:02.230 Neomorph and Adarx. They are buying cutting -edge 00:37:02.230 --> 00:37:04.929 technology rather than inventing all of it internally. 00:37:05.269 --> 00:37:07.030 And here's where it gets really interesting for 00:37:07.030 --> 00:37:09.659 you, the listener. What does this constant cycle 00:37:09.659 --> 00:37:11.800 of buying pipelines mean for fundamental innovation? 00:37:12.079 --> 00:37:14.599 Is the future of pharmaceutical development going 00:37:14.599 --> 00:37:17.820 to rely primarily on this model, large, high 00:37:17.820 --> 00:37:21.039 capital players relying on integrating successful 00:37:21.039 --> 00:37:24.480 external startups rather than relying on internal 00:37:24.480 --> 00:37:26.739 discovery within the major corporations themselves? 00:37:27.139 --> 00:37:29.679 It's a great question. Does the M &A model accelerate 00:37:29.679 --> 00:37:31.840 the delivery of new drugs by providing massive 00:37:31.840 --> 00:37:34.900 capital? Or does it stifle true diversity in 00:37:34.900 --> 00:37:36.900 research by concentrating all the profitable 00:37:36.900 --> 00:37:39.420 assets in the hands of a few giants? That's the 00:37:39.420 --> 00:37:41.280 core question that will define the next decade 00:37:41.280 --> 00:37:44.480 of medicine. And how do we as a society reconcile 00:37:44.480 --> 00:37:47.460 a company operating at this necessary global 00:37:47.460 --> 00:37:50.280 scale, providing critical treatments for millions 00:37:50.280 --> 00:37:53.280 with the profound corporate finance issues related 00:37:53.280 --> 00:37:56.340 to aggressive tax strategy and maintaining competitive 00:37:56.340 --> 00:37:59.780 ethical markets? It's a delicate balance between 00:37:59.780 --> 00:38:02.159 global scale and corporate responsibility that... 00:38:02.320 --> 00:38:04.519 will continue to navigate under the microscope 00:38:04.519 --> 00:38:07.280 for years to come. That's a question worth exploring 00:38:07.280 --> 00:38:09.059 long after this deep dive is over.